{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T02:26:27Z","timestamp":1779157587187,"version":"3.51.4"},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2017,7,28]]},"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-\u03b1 inhibitor (TNFi).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Using the Corrona RA registry, patients were identified who initiated ABA or a TNFi (June 2004\u2013January 2015), had a followup visit 6 months (\u00b1 3 mos) after initiation, and anti-CCP measured at or prior to initiation. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) from initiation to 6 months. Treatment response was evaluated based on a typical patient profile (female, aged 57 yrs, body mass index of 30 kg\/m<jats:sup>2<\/jats:sup>, baseline CDAI of 20, 1 prior biologic, and no comorbidities other than RA). Secondary outcomes included remission and low disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>There were 566 ABA initiators [anti-CCP+ (\u2265 20 units\/ml): n = 362; anti-CCP\u2212 (&lt; 20 units\/ml): n = 204] and 1715 TNFi initiators (anti-CCP+: n = 1113; anti-CCP\u2212: n = 602). Differences between treatment groups included baseline disease duration, CDAI, and prior biologic use. At 6 months, anti-CCP+ ABA initiators were associated with significantly greater CDAI response versus anti-CCP\u2212 ABA initiators; no significant difference was observed for TNFi initiators. When considering a typical RA patient profile, CDAI response was greater in anti-CCP+ versus anti-CCP\u2212 ABA initiators; anti-CCP+ versus anti-CCP\u2212 TNFi initiators were similar. Secondary outcome responses were also greater in anti-CCP+ versus anti-CCP\u2212 ABA initiators; TNFi initiators did not differ by anti-CCP status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>In a US-based clinical practice setting, anti-CCP status was associated with a differential treatment response to ABA, but not TNFi.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.170007","type":"journal-article","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:12:05Z","timestamp":1509581525000},"page":"32-39","source":"Crossref","is-referenced-by-count":46,"title":["Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-\u03b1 Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study"],"prefix":"10.3899","volume":"45","author":[{"given":"Leslie R.","family":"Harrold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Litman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean E.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evo","family":"Alemao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"2025062500200949000_45.1.32.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025062500200949000_45.1.32.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei111"},{"key":"2025062500200949000_45.1.32.3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/ar395","article-title":"Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value","volume":"4","author":"van Boekel","year":"2002","journal-title":"Arthritis Res"},{"key":"2025062500200949000_45.1.32.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025062500200949000_45.1.32.5","doi-asserted-by":"publisher","DOI":"10.1186\/ar1767"},{"key":"2025062500200949000_45.1.32.6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089442"},{"key":"2025062500200949000_45.1.32.7","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-eular.1790","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"74","author":"Sokolove","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025062500200949000_45.1.32.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203565"},{"key":"2025062500200949000_45.1.32.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21649"},{"key":"2025062500200949000_45.1.32.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.03.003"},{"key":"2025062500200949000_45.1.32.11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-14-34"},{"key":"2025062500200949000_45.1.32.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130905"},{"key":"2025062500200949000_45.1.32.13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000345"},{"key":"2025062500200949000_45.1.32.14","first-page":"S666","article-title":"The impact on anti-citrullinated protein antibody isotypes and epitope fine specificity in patients with early RA treated with abatacept and methotrexate","volume":"66","author":"Huizinga","year":"2014","journal-title":"Arthritis Rheum"},{"key":"2025062500200949000_45.1.32.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111315"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T07:20:22Z","timestamp":1750836022000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,1]]},"published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.3899\/jrheum.170007"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170007","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]}}}